Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P18085
UPID:
ARF4_HUMAN
Alternative names:
-
Alternative UPACC:
P18085; B2R7J7; P21371
Background:
ADP-ribosylation factor 4 (ARF4) is a pivotal GTP-binding protein, serving as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. It plays a crucial role in protein trafficking, potentially influencing vesicle budding and uncoating within the Golgi apparatus. Its involvement in these cellular processes underscores its importance in maintaining cellular function and integrity.
Therapeutic significance:
Understanding the role of ADP-ribosylation factor 4 could open doors to potential therapeutic strategies. Its central role in protein trafficking and modulation within the Golgi apparatus highlights its potential as a target for therapeutic intervention in diseases where protein trafficking is compromised.